Navigation Links
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
Date:6/5/2008

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MGd, Xcytrin(R)) in combination with Yttrium-90 Ibritumomab Tiuxetan (Zevalin(TM)), an approved antibody-targeted radiation therapy. The data were presented during the 10th International Conference on Malignant Lymphoma being held this week in Lugano, Switzerland.

The Phase 1/2 study was conducted in 29 patients with advanced relapsed lymphomas, including 11 patients with aggressive lymphomas. Eighty-three percent of the patients were rituximab (Rituxan(R)) refractory. Patients were treated with a standard dose of Zevalin administered with 2.5 to 5.0 mg/kg of MGd given for six days. Of 28 evaluable patients, 46 percent showed a complete response and 11 percent showed a partial response for an overall response rate of 57 percent. Rituximab refractory patients showed an overall response rate of 86 percent, with a 64 percent complete response rate and a median time to progression of 14 months. Adverse events seen were related to bone marrow suppression, an expected side effect of treatment with Zevalin.

"Motexafin gadolinium has been shown to have single agent activity in lymphoma and is synergistic with radiation therapy. This study shows a high rate of durable complete responses, especially in rituximab refractory patients," said Andrew M. Evens, D.O., M.S., Department of Hematology/Oncology, Northwestern University Feinberg School of Medicine, and lead author of the study.

Pharmacyclics has been developing MGd for use in combination
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... A study has found that ...ue for imaging the breast, is not affected by eith...o factors that limit the effectiveness of standard...will be presented today at the annual meeting of t..., , "The ability of PEM to detect cancer do...
(Date:12/1/2008)...S*BIO Pte Ltd today announced the initiation of a ...rally-active JAK2 inhibitor, in leading medical ce...athic myelofibrosis (CIMF). , , The trial ...y of SB1518 in patients with CIMF and is expected ...he study will assess the safety profile and evalua...
(Date:12/1/2008)...e is a two-way switch that, if turned off, causes ...that they lose their identity and become more like..., Dec. 1 Scientists at...ered that a certain differentiated cell type is so... constant expression of a gene called Prox1 to d...
(Date:12/1/2008)... Following a,Request fo...re an MVA-based,third generation smallpox vaccin...n behalf of the Canadian Department of National De...for the delivery of IMVAMUNE(R). , The Cana... of the,country,s bio-preparedness programme. , ...
Breaking Medicine Technology:New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Pain Relief Network Sues to Halt Government Actions Taken Against Kansas Patients 12148 1Pain Relief Network Sues to Halt Government Actions Taken Against Kansas Patients 12148 2Darwin Introduces Enhancements to its Lawyers Professional Liability Insurance Policy Including Privacy Wrongful Acts and More 12143 1Darwin Introduces Enhancements to its Lawyers Professional Liability Insurance Policy Including Privacy Wrongful Acts and More 12143 2Darwin Introduces Enhancements to its Lawyers Professional Liability Insurance Policy Including Privacy Wrongful Acts and More 12143 3Edwards Lifesciences Announces Organizational Changes 3356 1Edwards Lifesciences Announces Organizational Changes 3356 2Research uncovers the social dynamics of yellow jackets 2253 1Research uncovers the social dynamics of yellow jackets 2253 2Research uncovers the social dynamics of yellow jackets 2253 3Research uncovers the social dynamics of yellow jackets 2253 4
(Date:12/1/2008)...President on U.S. HIV/AIDS Initiatives and Accompl...l Forum on Global Health , , WASHINGTON, De...honored on the 20th anniversary of World AIDS Day ...en by Dr. Rick Warren on behalf of the Global PEAC...lobal Health. The award, given in recognition of ...
(Date:12/1/2008)... Over Prior Year Quarter --, -- Fully In... and Sharpened Commercial Foc... , RICHMOND, BC, Dec. 1 /PRNewswire-FirstCall/ ...ar device company, today announced financial resul...tember 30, 2008. , Neovasc Chief Executive Offi...
(Date:12/1/2008)...gher mortality and lower surgery rates in women ve...kage may be related to the complexity of evaluatin...findings of a Mayo Clinic study published this mon...l valve prolapse affects approximately 150 million...ry, preferably valve repair rather than replacemen...
(Date:12/1/2008)...repreneur, television and,radio host Ryan Seacres...,Bendheim will be honored by the Cedars-Sinai Boa...Gala, December 2, 2008, at the Hyatt Regency Centu...rd of Governors, co-chairs the,event with Debbee ...e "Road To,A Cure" Gala is sponsored by Lexus, wh...
Breaking Medicine News(10 mins):Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 11Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
... scientists have successfully converted human embr...e that in future, replacement cartilage could be g...and medical // problems, including sports injuries... replacements, and even for cosmetic and reconstru...
...nts in the United Kingdom may be at a high risk of...nducted by a team of researchers randomly on 250 G...eir // patients were overdosing on vitamins and re...e placing upon their body. A large number of pati...
...are developing tests that can identify the beginni...signs of the disease emerge. The researchers, who...annual meeting of the Society for Neuroscience in ...hem to single out people who went on to develop th...
...illicit use of drugs is on the rise in England, ac...0 admissions to the emergency department each year...with // patients visiting the emergency department...The doctor in charge of emergency care was also as...
Other Medicine News:Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Vitamin Abuse Syndrome In the UK 2Health News:Diagnosis of Alzheimer's years before clinical signs emerge 2
Nitinol Flat Wire Basket
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity.
Medicine Products: